Merlin Biotech, Inc.
February 26, 2024
Oncology
MERLIN Biotech is a pre-clinical stage mRNA platform company with a novel 1st in class cancer immunotherapy with exclusive IP in major worldwide markets. Our target, USP6, has demonstrated invivo efficacy with supporting human epidemiological survival data. These data support a broad cancer indication with an adult market estimated 5 year sales at $2 billion
)
){kind=logo}
)
){kind=logo}
){kind=logo}